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Objective: To date, no study has focused on the incidence and effects of prosthesis–patient mismatch in patients
requiring aortic valve replacement for aortic insufficiency. We hypothesized that the incidence and implications of
prosthesis–patient mismatch in patients with aortic insufficiency might be different than for aortic stenosis or mixed
disease because the annulus is generally larger in aortic insufficiency and left ventricular remodeling might differ.
Methods: Ninety-eight patients with lone aortic insufficiency (3þwith a preoperative mean gradient<30 mm
Hg) were followed over 7.7 4.3 years (maximum, 17.5 years) with clinical and echocardiographic assessments.
They were compared with 707 patients who had aortic valve replacement for aortic stenosis or mixed disease.
Prosthesis–patient mismatch was defined as an in vivo indexed effective orifice area of 0.85 cm2/m2 or less.
Results: Compared with patients with aortic stenosis/mixed disease, patients with aortic insufficiency had ap-
proximately half the incidence of prosthesis–patient mismatch (P ¼ .003). Patients with prosthesis–patient mis-
match had significantly higher transprosthesis gradients postoperatively. An independent detrimental effect of
prosthesis–patient mismatch on survival was observed in patients with aortic stenosis/mixed disease who had pre-
operative left ventricular dysfunction (hazard ratio, 2.3; P ¼ .03) but not in patients with aortic insufficiency,
irrespective of left ventricular function (hazard ratio, 0.7; P ¼ .7). In patients with aortic stenosis/mixed disease
with left ventricular dysfunction, prosthesis–patient mismatch predicted heart failure symptoms by 3 years after
aortic valve replacement (odds ratio, 6.0; P ¼ .002), but there was no such effect in patients with aortic insuffi-
ciency (P ¼ .8). Indexed left ventricular mass regression occurred to a greater extent in patients with aortic in-
sufficiency than in patients with aortic stenosis/mixed disease (by an additional 29  5 g/m2, P< .001), and
there was a trend for prosthesis–patient mismatch to impair regression in patients with aortic insufficiency (by
30  17 g/m2, P ¼ .1).
Conclusions: The incidence and significance of prosthesis–patient mismatch differs in patients with aortic insuf-
ficiency compared with those with aortic stenosis or mixed disease. In patients with aortic insufficiency, prosthe-
sis–patient mismatch is seen less frequently and has no significant effect on survival and freedom from heart
failure but might have a negative effect on left ventricular mass regression.
Price et al Acquired Cardiovascular DiseaseAortic valve replacement (AVR) is the mainstay of treat-
ment for patients with severe aortic valve stenosis, aortic in-
sufficiency (AI), or both. By relieving the obstruction with
a competent valve prosthesis, AVR increases survival, im-
proves congestive heart failure (CHF) symptoms, and allows
for left ventricular (LV) hypertrophy to regress.1 However,
the ability of the prosthesis to allow unimpeded blood
flow might be suboptimal because of the prosthesis’s size,
type, and orientation combined with patient factors, such
as body size. When present, such a scenario has been called
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continue to be studied in the cardiac surgical literature.
The significance of PPM in patients who have undergone
AVR is controversial. Although some have reported that
PPM is a rare phenomenon with little effect on patient out-
comes,2,3 others have shown that PPM is common and asso-
ciated with decreased LV mass regression,4,5 increased
recurrence of CHF symptoms,6,7 and increased mortal-
ity.6,8-12 We previously showed that PPM at an indexed ef-
fective orifice area (iEOA) equal to or less than 0.85 cm2/m2
of body surface area (BSA) primarily affects patients with
a preoperative left ventricular ejection fraction (LVEF) of
less than 50%10; within this group, patients with PPM expe-
rienced less complete LV mass regression, less freedom
from CHF, and decreased survival.
Indications for AVR include patients with aortic stenosis
(AS), AI, or a combination of both (mixed disease).1 The
heterogeneous nature of the pathology mandating AVR
might have been a confounding factor in studies, including
our own, that have examined the effect of PPM after
AVR. Compared with AS, AI may have distinct causesardiovascular Surgery c Volume 138, Number 3 639
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AI ¼ aortic insufficiency
AS ¼ aortic stenosis
AVR ¼ aortic valve replacement
BSA ¼ body surface area
CHF ¼ congestive heart failure
CI ¼ confidence interval
EOA ¼ effective orifice area
HR ¼ hazard ratio
iEOA ¼ indexed effective orifice area
LV ¼ left ventricular
LVEF ¼ left ventricular ejection fraction
OR ¼ odds ratio
PPM ¼ prosthesis–patient mismatch
and different effects on the left ventricle; at the time of sur-
gical intervention, the aortic annulus and left ventricle are
more often enlarged in patients with AI than in those with
AS. Therefore it is conceivable that the incidence of PPM,
the extent of post-AVR remodeling, and the clinical and
echocardiographic effect of PPM might differ between
patients with AI and AS.
To our knowledge, no published study has specifically ex-
amined the incidence and effect of PPM in patients with AI
versus that seen in patients with AS. We investigated the in-
cidence of PPM and its effects on survival, freedom from
CHF and CHF-related death, and LV mass regression in
patients with AI compared with those with AS or mixed
disease.
MATERIALS AND METHODS
Patient Population and Clinical Follow-up
The patient population consisted of 805 adult patients who underwent
AVR at the University of Ottawa Heart Institute between 1990 and 2003.
This cohort was the subject of a previous publication.13 It has since been up-
dated and further validated through review of individual patient character-
istics by 3 external observers. Follow-up was completed to February 1,
2008.
All patients received a prosthesis that is still commercially available in
North America. Only patients who survived the operation and were fol-
lowed up annually at least once in a dedicated valve clinic were included
in the analyses. Patients who underwent concomitant mitral valve repair
or replacement were excluded. At each clinic visit, patients had a history
taken that was focused on the determination of functional status and the oc-
currence of valve-related complications, a physical examination, electrocar-
diography, chest radiography, a complete blood count, serum chemistries,
and international normalized ratio determinations (when applicable). Pa-
tients received anticoagulation treatments according to guidelines in effect
at the time, as previously described.14
AI was defined as echocardiographic severity of grade 3 or 4 with a mean
transvalvular gradient of less than 30 mm Hg. AS or mixed disease was de-
fined as a patient who did not meet the criteria for pure AI. Persistence or
recurrence of heart failure after AVR was defined as the composite end point
of New York Heart Association functional class III or IV symptoms for
more than 4 consecutive weeks or death for which the primary or contribut-640 The Journal of Thoracic and Cardiovascular Suing diagnosis was CHF.7,9 Clinical impressions were corroborated with
physical examination, chest radiographic, electrocardiographic, and echo-
cardiographic findings. Prosthesis-related complications were recorded ac-
cording to the ‘‘Guidelines for reporting morbidity and mortality after
cardiac valvular operations.’’15 The total follow-up was 6174 patient-years,
with a mean duration of 7.7  4.3 years (range, 60 days–17.5 years).
Prostheses
Prosthesis type and size were recorded for all patients. Prostheses were
implanted and oriented according to the manufacturer’s instructions. The
prostheses used were Medtronic Hancock II (Medtronic, Minneapolis,
Minn) in 223 (28%) patients, St Jude Medical Standard (St Jude Medical,
St Paul, Minn) in 151 (19%) patients, Carbomedics (Sulzer CarboMedics,
Austin, Tex) in 137 (17%) patients, Medtronic Hall in 89 (11%) patients,
homograft in 58 (7%) patients, Medtronic Hancock I in 47 (6%) patients,
St Jude Medical HP in 45 (6%) patients, Edwards Perimount (Edwards
Lifesciences, Irvine, Calif) in 38 (5%) patients, MCRI On-X (Medical Car-
bon Research Institute, Austin, Tex) in 8 (1%) patients, stentless porcine in
5 (0.6%) patients, and Carpentier-Edwards Standard in 4 (0.5%) patients.
The in vivo effective orifice area (EOA) for each prosthesis type and size
was obtained from the literature of patients with normally functioning pros-
theses16 and averaged if more than 1 published value was available. This
was supplemented with data provided by the valve manufacturer if pub-
lished data were insufficient with respect to a given prosthesis size. The
iEOA was obtained by dividing the in vivo EOA by the patient’s BSA at
the time of the operation and was available for all patients. PPM was defined
as an iEOA of 0.85 cm2/m2 or less for the purpose of examining clinical and
echocardiographic outcomes.
Echocardiographic Follow-up
Patients underwent a complete M-mode, 2-dimensional, Doppler trans-
thoracic echocardiogram before AVR and underwent serial echocardio-
graphic examinations on a biannual basis or as clinically indicated after
AVR. Peak instantaneous and mean transvalvular or transprosthesis pres-
sure gradients were derived by using modified Bernoulli equations at
each echocardiographic examination. LV end-diastolic and end-systolic di-
ameters, septal and posterior wall thicknesses, and left atrial anteroposterior
diameters were measured from the M-mode recordings according to the rec-
ommendations of the American Society of Echocardiography.17 LV mass
was calculated from these values by using the modified formula of the
American Society of Echocardiography.18 LVEF was quantified by means
of visual estimation by 1 or more of 4 blinded observers.19 LV systolic func-
tion was graded as 1 (normal, LVEF 50%), 2 (mildly impaired, LVEF
40% to 49%), 3 (moderately impaired, LVEF 30% to 39%), or 4 (severely
impaired, LVEF<30%). Patients were divided into those with normal
(LVEF50%) and impaired (LVEF<50%) LV systolic function to assess
the effect of PPM according to preoperative LV function.
The latest preoperative echocardiogram and the echocardiogram corre-
sponding to the lowest postoperative LV mass during the follow-up period
were used to determine the maximum LV mass regression in each patient.
For transprosthesis pressure gradients, we arbitrarily used the echocardio-
graphic examination closest to 18 months postoperatively. This was aimed
at allowing LV mass regression to occur while minimizing the likelihood of
prosthesis-related issues.10,15
Statistical Analyses
Data were analyzed with Intercooled Stata 10.1 software (StataCorp,
College Station, Tex). Continuous data are presented as the mean  SD
or the mean (lower 95% confidence limit and upper 95% confidence limit).
Prosthetic valve hemodynamics. Peak and mean instantaneous
gradients were compared between patients with and without PPM by using
2-sample t tests within the subgroups of patients with (1) AS or mixedrgery c September 2009
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mixed disease and LV dysfunction (LVEF<50%) preoperatively, (3) AI
and normal LV function preoperatively, and (4) AI and LV dysfunction pre-
operatively.
Survival. Potential predictors of survival, operative indication (includ-
ing LV function), and PPM were tested for equality with a log-rank test.
For multivariate models, the proportional hazard assumption was tested
with generalized Cox–Snell residuals. If the assumption was met, Cox pro-
portional hazards models were developed by incorporating variables that
had a P value of .05 or less on log-rank testing, by forcing the risk factors
for decreased survival after AVR identified previously (ie, age, atrial fibril-
lation, preoperative heart failure functional class, and coronary artery dis-
ease) into the model,7 and by incorporating patient characteristics that
differed between the mismatch and no-mismatch groups, including sex
and the type of prosthesis, into the model. To account for confounding,
no automated model selection procedure was used, and all covariates
were used simultaneously.
Heart failure. The effects of PPM on the cumulative incidence of heart
failure symptoms or heart failure–related death within 3 years after AVR in
each of the 4 subgroups of normal and impaired preoperative LV function
and valvular lesion, AS, or AI, were examined by using a c2 test. A 3-
year period was arbitrarily chosen to allow symptom improvement and
LV remodeling in the greatest potential number of cohort patients7,20 while
minimizing the possible confounding effects of early structural valve dete-
rioration on heart failure symptoms.21 Multivariable logistic regression
models incorporated the risk factors for decreased freedom from heart fail-
ure after AVR identified previously7 and patient characteristics that differed
between the groups with and without PPM.
LV mass regression. Echocardiographic LV mass changes were de-
rived from the lowest postoperative echocardiographically derived LV mass
minus the preoperative LV mass. These changes were indexed to the pa-
tient’s preoperative BSA. Changes were compared between patients with
and without PPM within the 4 subgroups by using 2-sample t tests.
RESULTS
Table 1 shows the patient and operative characteristics
of the cohort according to the condition that led to AVR.
Patients with PPM in the AS or mixed disease group were
more often female and older and more often had coronary
artery disease. In both the AI and the AS or mixed disease
groups, PPM was more often associated with use of a
bioprosthetic valve.
PPM Determined by Using In Vivo EOA Values
Predicts Prosthetic Valve Hemodynamics After AVR
At a mean of 1.6  1.7 years after surgical intervention,
patients with PPM determined on the basis of in vivo
EOA (see the Methods section)16 had higher peak and
mean instantaneous transprosthesis gradients compared
with patients without PPM (peak, 29.7  12.9 vs 25.2 
11.4 mm Hg; mean, 16.6  7.3 vs 13.7  6.2 mm Hg, re-
spectively; P< .001). For patients undergoing operations
for AS or mixed disease, the average difference in peak
and mean gradients between those with PPM and those with-
out PPM was 3.8 and 2.4 mm Hg, respectively (P< .001).
For patients undergoing operations for AI, the average dif-
ference in peak and mean gradients between those with
PPM and those without PPM was 10.1 and 6.2 mm Hg, re-
spectively (P< .001). Within the AS/mixed subgroup andThe Journal of Thoracic andthe AI subgroup, PPM had a similar effect on postoperative
peak and mean transprosthesis gradients among patients
with normal and impaired LV function preoperatively
(data not shown).
PPM Is Less Common When AVR Is Performed
for AI
After AVR, the incidence of PPM was significantly lower
in patients with AI (26/98 [26.5%] patients) than in patients
with AS or mixed disease (299/707 [42.3%] patients, P ¼
.003). A rheumatic cause was present in 3 of the patients
with AI, 1 of whom had PPM after AVR.
PPM Negatively Affects Survival, Freedom From
Heart Failure, and LV Mass Regression if LV
Dysfunction Is Present Before the Operation in
Patients With AS but Not in Patients With AI
Effect on survival. Figure 1 displays the survival of pa-
tients with AS or mixed disease after AVR. After adjustment
for confounding variables, patients as a whole did not expe-
rience significantly worse survival with PPM (hazard ratio
[HR], 1.4; 95% confidence interval [CI], 0.9–2.1; P ¼ .1).
However, if LV dysfunction existed at the time of the oper-
ation, PPM was associated with worse survival (HR, 2.3;
95% CI, 1.1–4.8; P ¼ .03).
In contrast, this phenomenon was not observed in patients
who had AVR for lone AI (Figure 2). In these patients mis-
match did not affect survival in the entire group of patients
with AI (HR, 0.7; 95% CI, 0.2–3.4; P ¼ .7) nor did it affect
survival in patients with AI who had LV dysfunction preop-
eratively (HR, 1.0; 95% CI, 0.1–8.1; P ¼ .9).
Effect on freedom from heart failure. The overall inci-
dence of persistent or recurrent CHF symptoms by 3 years
after AVR was 11.9% in patients with AS or mixed disease
and 11.5% in patients with lone AI, respectively (P ¼ .9).
In patients with AS or mixed disease, PPM did not signif-
icantly increase the risk of persistent or recurrent CHF symp-
toms if the LV systolic function was good preoperatively
(odds ratio [OR] for PPM versus no PPM, 1.7; 95% CI,
0.6–4.6; P ¼ .3). However, if impaired LV function was
present, mismatch was associated with significantly more
CHF symptoms (OR, 6.2; 95% CI, 1.7–22.5; P ¼ .005).
In patients with lone AI, this phenomenon was not ob-
served. Mismatch did not significantly increase the risk of
persistent or recurrent CHF symptoms, regardless of
whether the LV systolic function was normal (OR, 2.4;
P ¼ .6) or impaired preoperatively (P ¼ .6).
Effect on LV Mass Regression. Figure 3 depicts the extent
of maximum LV mass regression over the follow-up period
in the various subgroups. Maximum LV mass regression
was observed at a mean of 5.4  3.5 years in the AS or
mixed disease group and 6.3  3.8 years in the lone AI
group.Cardiovascular Surgery c Volume 138, Number 3 641
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Aortic insufficiency Aortic stenosis or mixed disease
No mismatch (n ¼ 72) Mismatch (n ¼ 26) P value No mismatch (n ¼ 408) Mismatch (n ¼ 299) P value
Preoperative characteristics
Male sex 56 (77.8%) 18 (69.2%) .4 292 (71.6%) 169 (56.5%) <.001
Age (y) 55.1  15.1 61.0  14.7 .1 59.8  13.3 71.8  9.6 <.001
Body surface area (m2) 1.83  0.25 1.96  0.21 .01 1.82  0.23 1.94  0.22 <.001
Coronary artery disease 11 (15.3%) 8 (30.8%) .1 125 (30.6%) 124 (41.5%) .003
Atrial fibrillation 9 (12.5%) 6 (23.1%) .2 44 (10.8%) 43 (14.4%) .2
NYHA class
I 14 (19.4%) 4 (15.4%) .7 103 (25.3%) 74 (24.8%) .2
II 18 (25.0%) 5 (19.2%) 125 (30.6%) 72 (24.1%)
III 21 (29.2%) 11 (42.3%) 121 (29.7%) 109 (36.5%)
IV 19 (26.4%) 6 (23.1%) 59 (14.5%) 44 (14.7%)
Left ventricular grade*
1 49 (68.1%) 18 (69.2%) .8 266 (65.2%) 215 (71.9%) .3
2 10 (13.9%) 4 (15.4%) 72 (17.7%) 39 (13.0%)
3 10 (13.9%) 4 (15.4%) 41 (10.1%) 27 (9.0%)
4 3 (4.2%) 0 29 (7.1%) 18 (6.0%)
Previous AVR 25 (34.8%) 11 (42.3%) .5 66 (16.2%) 32 (10.7%) .04
Emergency operation 1 (1.4%) 1 (4.0%) .4 11 (2.7%) 7 (2.4%) .8
Operative characteristics
Bioprosthetic valve 18 (25.0%) 17 (65.4%) <.001 91 (22.3%) 245 (81.9%) <.001
Aortic root enlargementy 2 (2.8%) 2 (7.7%) .3 44 (10.8%) 30 (10.0%) .8
Mismatch refers to prosthesis–patient mismatch, which is defined as a ratio of the prosthesis’s effective orifice area over the patient’s body surface area equal to or less than
0.85 cm2/m2. P values refer to the comparison between mismatch and no-mismatch patients within the aortic insufficiency and aortic stenosis or mixed disease groups. Data are
presented as the mean  SD or number (percentage). NYHA, New York Heart Association; AVR, aortic valve replacement. *Grade 1, Left ventricular ejection fraction of 50% or
more; grade 2, ejection fraction of 40% to 49%; grade 3, ejection fraction of 30% to 39%; grade 4, ejection fraction of less than 30%. yConsists of annular (Nicks, Manougian, or
Konno) or aortic root enlargement with pericardium or Dacron.LV mass regression occurred to a greater degree in pa-
tients with AI than in patients with AS or mixed disease
(by an additional 29 g/m2; 95% CI, 18–40; P<.001). In pa-
tients with AS or mixed disease, there was no significant dif-
ference in mass regression as a result of PPM if the left
ventricle was normal preoperatively (P ¼ .9). However, in
patients with LV dysfunction, PPM was associated with a de-
crease in the extent of postoperative LV mass regression (by
20 g/m2; 95% CI, 6–35; P ¼ .007).
In patients with AI, PPM was associated with a possible
decrease in postoperative LV mass regression (by 29 g/m2;
95% CI,3 to 61; P ¼ .1 if the left ventricle was normal;
by 33 g/m2; 95% CI,53 to 119; P ¼ .4 if the left ventricle
was depressed). However, neither scenario reached statisti-
cal significance.
DISCUSSION
The concept of PPM was initially described by Rahim-
toola in 1978.22 It was defined as the implantation of a pros-
thesis with an EOA less than that of the normal human aortic
valve. Since that time, the definition has evolved to describe
a scenario in which the EOA of a prosthesis is too small in
relation to patient body size, resulting in abnormally high
transprosthesis pressure gradients.23 More specifically,
most authors have adopted a definition of iEOA of less642 The Journal of Thoracic and Cardiovascular Suthan 0.85 for PPM.16 Others have adopted more stringent
definitions8,11 or even a continuum of severity with an
iEOA of less than 0.65 defined as severe PPM.9,23
PPM after AVR has been studied extensively since its de-
scription. There is accumulating evidence that this entity is
associated with poor outcomes in specific subsets of pa-
tients.10,11,13 Previously inconsistent results in studies exam-
ining the effects of PPM might have been attributable to
interaction or confounding from the presence of certain
risk factors, such as older age, large body mass index, and
pre-existing LV dysfunction. The valve lesion could have
been one of these effect-modifying factors as well; in this re-
gard this is the first study to specifically examine the clinical
effect of PPM in patients undergoing AVR for AI.
The main findings of this study were that PPM is seen less
frequently in patients with AI than in those with AS. In con-
trast to AS, PPM does not affect clinical outcomes after
AVR for AI. However, there might still be suboptimal re-
gression of LV mass in patients with AI and PPM, and
this aspect is in need of more study with a greater number
of patients.
Specifically, we found that PPM is seen in patients with AI
nearly half as frequently as in patients with AS. The overall
incidence of PPM was 40%, which is consistent with pre-
vious reports.4,9,11,12 Although PPM decreased survival inrgery c September 2009
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ference was seen in survival for patients with AI with
PPM, regardless of preoperative LV function. Patients with
AS with PPM had 6 times the odds of CHF symptoms and
death at 3 years if their LVEF was subnormal. This pattern
was not seen in patients with AI, regardless of LV function.
Only patients with AS with LV dysfunction and PPM had
significantly decreased LV mass regression. Interestingly,
in patients with AI, there was a trend toward reduced regres-
sion in patients with normal LV function and PPM. However,
this finding was not statistically significant. Taken together,
the results of this study suggest that PPM is encountered
less frequently in patients with AI and is more clinically in-
dolent. Special technical maneuvers to facilitate the implan-
tation of a valve of larger iEOA might increase perioperative
morbidity and mortality and therefore do not seem justified in
patients with AI on the basis of improving long-term survival
or freedom from CHF symptoms and death.
These data also substantiate our previously published rec-
ommendations10 that in patients with AS and LV dysfunc-
tion, a PPM threshold of 0.85 represents a minimum
prosthesis size for optimal survival, freedom from CHF,
and LV mass regression after AVR. In patients with AS or
mixed disease, measures to ensure implantation of an ade-
quately large prosthesis to avoid PPM seem justified. The ef-
fects of PPM on the subgroup of patients with AS and LV
FIGURE 1. Long-term survival after aortic valve replacement with ad-
justed hazard ratios in all patients with aortic stenosis or mixed disease
(A) and patients with aortic stenosis or mixed disease and preoperative
left ventricular dysfunction (B). The subset of patients with preoperative
left ventricular dysfunction experienced significantly worse long-term sur-
vival in the presence of prosthesis–patient mismatch (PPM). 95% CI,
95% Confidence interval.
FIGURE 2. Long-term survival after aortic valve replacement with ad-
justed hazard ratios in all patients with aortic insufficiency (A) and patients
with aortic insufficiency with preoperative left ventricular dysfunction (B).
Prosthesis–patient mismatch (PPM) did not affect long-term survival in pa-
tients with aortic insufficiency. 95% CI, 95% Confidence interval.The Journal of Thoracic and Cardiovascular Surgery c Volume 138, Number 3 643
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group10 and others.9 Because the definition of AS included
patients with mixed disease and was less stringent than
that of AI, the novel and specific findings of this study relate
primarily to the outcomes of patients with AI. It is possible
that some of the conflicting results observed in previous
studies of PPM might be explainable, at least in part, by
the effect modification between operative indication and
PPM identified in the present data.
Limitations
In this study we examined the effect of PPM on clinical and
echocardiographic outcomes according to LV function by
using normal versus decreased LVEF as the dichotomization
FIGURE 3. Indexed change in left ventricular (LV) mass in patients with
aortic stenosis or mixed disease and in patients with aortic insufficiency.
In patients with aortic stenosis and left ventricular dysfunction, those with
prosthesis–patient mismatch (PPM) experienced a significant reduction in
the regression of left ventricular hypertrophy. In patients with aortic insuf-
ficiency, a trend toward decreased reduction in left ventricular mass was
seen in those with normal left ventricular systolic function and prosthe-
sis–patient mismatch.644 The Journal of Thoracic and Cardiovascular Scriterion. We alternatively could have used dichotomization
by normal versus enlarged LV end-systolic or end-diastolic
dimensions, which are relevant to the management of pa-
tients with AI and were used in this study for LV mass deter-
minations. However, although these parameters might be
of prognostic importance in patients with AI as the operative
lesion, their use would have limited our ability to make infer-
ences in the subset of patients with AS/mixed disease, who
less commonly exhibit LV dilatation.1,24
Studies examining PPM are often affected by confound-
ing by indication and selection bias. Surgeons tend to avoid
root enlargement techniques or other high-risk maneuvers to
implant larger valves in high-risk patients. This might make
it spuriously appear that patients receiving smaller valves
have worse outcomes. We have attempted to control for
these issues through multivariable techniques; however,
the relationship between PPM and operative indication ob-
served in this observational study might have been modified
by unknown confounders not controlled for in the statistical
analyses.
The vast majority of patients in our series had AI based on
nonrheumatic causes. These patients tend to have dilated
aortic roots, and the results of this study might not be gener-
alizable to patients with rheumatic AI, in whom the aortic
annulus tends to be smaller. We believe, however, that these
results are valid in the context of operations performed in the
Western world, where rheumatic valvular disease is becom-
ing increasingly rare.1
We defined and quantified PPM by using the in vivo EOA
values derived from normally functioning valves. This
method has been used and externally validated in the litera-
ture previously25; furthermore, it was internally validated in
the present study as a strong correlate of actual prosthetic he-
modynamics in all subgroups. Using the EOA derived by us-
ing the Doppler echocardiographic continuity equation in
individual patients after prosthesis implantation has several
limitations related to the difficulty of accurately measuring
the LV outflow diameter caused by reverberations from
the prosthetic valve and the presence of large localized trans-
prosthesis gradients and nonflat transprosthesis spatial
velocity profiles, which frequently result in large discrep-
ancies.26-28 It was also recently demonstrated that the in
vivo EOA method provides superior sensitivity and specific-
ity for prediction of postoperative PPM in individual
patients.25
CONCLUSIONS
The incidence of PPM and the effect of PPM on survival,
freedom from heart failure, and LV mass regression after
AVR are dependent on operative indication. The incidence
of PPM in patients with AI after AVR is half of that seen
in patients with AS. In contrast to patients with AS, for pa-
tients with AI, PPM at a threshold of 0.85 has no effect on
survival or freedom from CHF. The results of this studyurgery c September 2009
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ceiving AVR for AS, measures to increase the iEOA of
the implanted valve should be reserved for the subset of pa-
tients with LV dysfunction. In patients with AI, however,
technical steps to avoid PPM after AVR do not appear justi-
fied solely on the basis of improving postoperative survival
or reducing the risk of CHF or CHF-related death.
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